[Pubmed] Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed ref
Posté : 24 juil. 2023 12:00
Int J Hematol. 2023 Jul 24. doi: 10.1007/s12185-023-03644-5. Online ahead of print.
ABSTRACT
A 37-year-old man with refractory classical Hodgkin lymphoma (cHL) underwent PD-1 blockade therapy with nivolumab, which resulted in a partial response. However, treatment was discontinued due to immune-related adverse events (irAEs), including myasthenia gravis and myositis. Retreatment with nivolumab resulted in a complete metabolic response and hepatic irAE. Subsequently, nivolumab was administered at extended dosing intervals. Intermittent infusion of ten doses of nivolumab for a total dose of 2400 mg/body helped control the relapsed/refractory cHL over three years. During nivolumab treatment, disease progression and emergence of irAEs were associated with the proportion of CD8 + T cells expressing nivolumab-free PD-1 relative to the total number of CD8 + T cells. The findings in this nivolumab-sensitive patient highlight the clinical utility of monitoring immune cells expressing nivolumab-free PD-1 in patients with cHL who have been treated with nivolumab and have experienced irAEs.
PMID:37488284 | DOI:10.1007/s12185-023-03644-5
Source: https://pubmed.ncbi.nlm.nih.gov/3748828 ... t6+86293ac